Angela C Hirbe
Overview
Explore the profile of Angela C Hirbe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiao K, Yang K, Hirbe A
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39857962
Malignant peripheral nerve sheath tumors (MPNSTs) are rare but aggressive malignancies with a low 5-year survival rate despite current treatments. MPNSTs frequently harbor mutations in key genes such as ,...
2.
Odhiambo D, Fan S, Hirbe A
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39857943
Malignant peripheral nerve sheath tumor (MPNST) is a rare but aggressive soft-tissue sarcoma characterized by poor response to therapy. The primary treatment remains surgical resection with negative margins. Nonetheless, in...
3.
Qin W, Peng C, Yang X, Jiang A, Zhong N, Liu Y, et al.
Cell Biol Toxicol
. 2024 Dec;
41(1):8.
PMID: 39707021
Synovial sarcoma (SS) is a rare soft tissue sarcoma characterized by high-grade malignancy and poor prognosis. Preliminary research indicates that apoptosis evasion is a key factor in SS progression, primarily...
4.
Moertel C, Hirbe A, Shuhaiber H, Bielamowicz K, Sidhu A, Viskochil D, et al.
J Clin Oncol
. 2024 Nov;
43(6):716-729.
PMID: 39514826
Purpose: Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration-approved for adults. Methods: ReNeu is an open-label, multicenter, pivotal, phase...
5.
Sundby R, Szymanski J, Pan A, Jones P, Mahmood S, Reid O, et al.
Clin Cancer Res
. 2024 Aug;
30(19):4363-4376.
PMID: 39093127
Purpose: Early detection of neurofibromatosis type 1 (NF1)-associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, enabling early definitive treatment and potentially averting deadly outcomes. In this study, we describe...
6.
Somaiah N, Paudyal B, Winkler R, Van Tine B, Hirbe A
Target Oncol
. 2024 Jul;
19(5):665-678.
PMID: 38954182
Background: Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet...
7.
Yan H, Hu Y, Lyu Y, Akk A, Hirbe A, Wickline S, et al.
bioRxiv
. 2024 Jul;
PMID: 38948794
Background: Oxidative stress is implicated in the pathogenesis and progression of abdominal aortic aneurysm (AAA). Antioxidant delivery as a therapeutic for AAA is of substantial interest although clinical translation of...
8.
Hirbe A, Dehner C, Dombi E, Eulo V, Gross A, Sundby T, et al.
Am Soc Clin Oncol Educ Book
. 2024 May;
44(3):e432242.
PMID: 38710002
Most malignant peripheral nerve sheath tumors (MPNSTs) are clinically aggressive high-grade sarcomas, arising in individuals with neurofibromatosis type 1 (NF1) at a significantly elevated estimated lifetime frequency of 8%-13%. In...
9.
Sundby R, Szymanski J, Pan A, Jones P, Mahmood S, Reid O, et al.
medRxiv
. 2024 Jan;
PMID: 38293154
Early detection of neurofibromatosis type 1 (NF1) associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, potentially averting deadly outcomes. Here, we describe a cell-free DNA (cfDNA) fragmentomic approach which...
10.
Wang J, Calizo A, Zhang L, Pino J, Lyu Y, Pollard K, et al.
Sci Adv
. 2023 Nov;
9(47):eadg8876.
PMID: 38000020
Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas with limited treatment options, and new effective therapeutic strategies are desperately needed. We observe antiproliferative potency of genetic...